Paper33536629
Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents.
Blanchard EL and 18 others. Nat Biotechnol, 2021. Cited by 180 papers, by iCite.
Cite this record
ConductScience Library. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents. Papers, record 33536629. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33536629
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Influenza, Human | Major topic |
| RNA, Messenger | Major topic |
| SARS-CoV-2 | Major topic |
| Animals | |
| CRISPR-Cas Systems | |
| Cricetinae | |
| Disease Models, Animal | |
| Humans | |
| Mice | |
| Orthomyxoviridae | |
| RNA, Viral | |
| Respiratory System |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| HR00111920008 | United States Department of Defense | Defense Advanced Research Projects Agency (DARPA) | PubMed |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22966141 | Human viruses: discovery and emergence. | Philos Trans R Soc Lond B Biol Sci | 2012 | https://conductscience.org/library/papers/22966141 | PubMed |
| 2 | 33028965 | Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. | Nat Microbiol | 2020 | https://conductscience.org/library/papers/33028965 | PubMed |
| 3 | 28655327 | Advances in the delivery of RNA therapeutics: from concept to clinical reality. | Genome Med | 2017 | https://conductscience.org/library/papers/28655327 | PubMed |
| 4 | 11377720 | A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. | J Virol Methods | 2001 | https://conductscience.org/library/papers/11377720 | PubMed |
| 5 | 31607545 | Programmable Inhibition and Detection of RNA Viruses Using Cas13. | Mol Cell | 2019 | https://conductscience.org/library/papers/31607545 | PubMed |
| 6 | 2398532 | Evolution of influenza A virus PB2 genes: implications for evolution of the ribonucleoprotein complex and origin of human influenza A virus. | J Virol | 1990 | https://conductscience.org/library/papers/2398532 | PubMed |
| 7 | 27978991 | Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. | Drug Discov Today Technol | 2016 | https://conductscience.org/library/papers/27978991 | PubMed |
| 8 | 19525932 | Emergence and pandemic potential of swine-origin H1N1 influenza virus. | Nature | 2009 | https://conductscience.org/library/papers/19525932 | PubMed |
| 9 | 30936432 | Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. | Nat Biomed Eng | 2019 | https://conductscience.org/library/papers/30936432 | PubMed |
| 10 | 25214632 | Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. | Science | 2014 | https://conductscience.org/library/papers/25214632 | PubMed |
| 11 | 27281742 | Approved Antiviral Drugs over the Past 50 Years. | Clin Microbiol Rev | 2016 | https://conductscience.org/library/papers/27281742 | PubMed |
| 12 | 28694997 | Antiviral drug resistance as an adaptive process. | Virus Evol | 2016 | https://conductscience.org/library/papers/28694997 | PubMed |
| 13 | 30933724 | A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. | Mol Ther Nucleic Acids | 2019 | https://conductscience.org/library/papers/30933724 | PubMed |
| 14 | 27256883 | C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. | Science | 2016 | https://conductscience.org/library/papers/27256883 | PubMed |
| 15 | 23245604 | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. | Lancet | 2012 | https://conductscience.org/library/papers/23245604 | PubMed |
| 16 | 30609147 | Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium. | Adv Mater | 2019 | https://conductscience.org/library/papers/30609147 | PubMed |
| 17 | 32353252 | Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. | Cell | 2020 | https://conductscience.org/library/papers/32353252 | PubMed |
| 18 | 32408338 | Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. | Nature | 2020 | https://conductscience.org/library/papers/32408338 | PubMed |
| 19 | 9182098 | Antiviral resistance: mechanisms, clinical significance, and future implications. | J Antimicrob Chemother | 1996 | https://conductscience.org/library/papers/9182098 | PubMed |
| 20 | 12594334 | RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. | Proc Natl Acad Sci U S A | 2003 | https://conductscience.org/library/papers/12594334 | PubMed |
Cited by134
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 180 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42886793 | Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition. | Sci Adv | 2026 | https://conductscience.org/library/papers/42886793 | PubMed |
| 42804049 | Plant viral suppressors HcPro and P19 inhibit CRISPR-Cas13-mediated transcript interference. | Stress Biol | 2026 | https://conductscience.org/library/papers/42804049 | PubMed |
| 42568525 | From neuraminidase inhibitors to novel mechanisms: expanding therapeutic strategies against influenza. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42568525 | PubMed |
| 42563266 | Nanomaterial Strategies for Pulmonary Delivery of Immunotherapeutics in Lung Cancer Treatment. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/42563266 | PubMed |
| 42524609 | In vivo delivery strategies for therapeutic CRISPR genome editing. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42524609 | PubMed |
| 42506633 | Engineered mRNA Nanoparticle Platforms for Respiratory Mucosal Delivery. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42506633 | PubMed |
| 42504705 | Intranasal drop of multiplex RNA therapy for SARS-CoV-2 infections: baicalein-enhanced FEN1 nuclease cleaving as a virus buster. | Emerg Microbes Infect | 2026 | https://conductscience.org/library/papers/42504705 | PubMed |
| 42493737 | Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery. | Chem Biol Drug Des | 2026 | https://conductscience.org/library/papers/42493737 | PubMed |
| 42380588 | Advancements in RNA-based therapies from bench to bedside. | NPJ Drug Discov | 2026 | https://conductscience.org/library/papers/42380588 | PubMed |
| 42283488 | Investigating the impact of poly(beta amino) ester-mediated FOXJ1 mRNA delivery on differentiation of primary human bronchial epithelial cells. | Biol Open | 2026 | https://conductscience.org/library/papers/42283488 | PubMed |
| 42258100 | The multifaceted challenge of viral nervous necrosis in fish farming: a review of current knowledge and control. | Vet Res Commun | 2026 | https://conductscience.org/library/papers/42258100 | PubMed |
| 42092617 | Development of a CRISPR-Cas13-based antiviral strategy against hepatitis E virus. | JHEP Rep | 2026 | https://conductscience.org/library/papers/42092617 | PubMed |
| 42071119 | The architecture of computational antiviralism: a multi-scale framework from molecular targeting to viral ecosystem engineering. | Mol Divers | 2026 | https://conductscience.org/library/papers/42071119 | PubMed |
| 42065115 | Broad-spectrum CRISPR-Cas13d-mediated strategy for combating human coronaviruses. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42065115 | PubMed |
| 41868473 | A hybrid polymeric system for pulmonary mRNA delivery: Advancing mucosal vaccine development. | Cell Biomater | 2026 | https://conductscience.org/library/papers/41868473 | PubMed |
| 41824765 | Programmable RNA N6,2´-O-Dimethyladenosine Editing. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41824765 | PubMed |
| 41705810 | Viral genome editing methods and applications in the CRISPR era. | J Virol | 2026 | https://conductscience.org/library/papers/41705810 | PubMed |
| 41673122 | Status and outlook of mRNA therapeutics for viral diseases. | EMBO Mol Med | 2026 | https://conductscience.org/library/papers/41673122 | PubMed |
| 41672307 | Engineered cargo-free nanoparticle decoys for phagocytic modulation of macrophages. | J Control Release | 2026 | https://conductscience.org/library/papers/41672307 | PubMed |
| 41568169 | Engineered CRISPR-Cas13a system with enhanced target RNA cleavage activity and reduced collateral activity for therapeutic applications. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/41568169 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33536629
GET https://conductscience.org/api/papers/v1/33536629/references?page=2